Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 23, Issue 15, 2005, Pages 3502-3508

  Hurwitz, Herbert I ^a   Fehrenbacher, Louis ^a   Hainsworth, John D ^a   Heim, William ^a   Berlin, Jordan ^a   Holmgren, Eric ^a   Hambleton, Julie ^a   Novotny, William F ^a   Kabbinavar, Fairooz ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLACEBO; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ALOPECIA; ARTICLE; BLEEDING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; EPISTAXIS; EXFOLIATIVE DERMATITIS; FEMALE; HUMAN; HYPERTENSION; LACRIMATION DISORDER; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISCOLORATION; TASTE AVERSION; TREATMENT RESPONSE; AGED; CANCER INVASION; CANCER STAGING; COLORECTAL TUMOR; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 20644432867     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.10.017     Document Type: Article

References (21)

1. Thirion P, Michiels S, Pignon JP, et al: Meta-Analysis Group in Cancer: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. J Clin Oncol 22:3766-3775, 2004 [erratum in J Clin Oncol 23:1337-1338, 2005]
2. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 330:1136-1142, 1994
3. Thirion P, Michiels S, Pignon JP, et al: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. J Clin Oncol 22:3766-3775, 2004
4. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
5. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
6. Freyer G, Rougier P, Bugat R, et al: Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure: CPT-11 F205, F220, F221 and V222 study groups. Br J Cancer 83:431-437, 2000
7. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997
8. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
9. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18:4-25, 1997
10. Folkman J: Antiangiogenic therapy, in DeVita VTJ, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott-Raven, 1997, pp 3075-3085
11. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
12. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
13. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
14. Saltz LB, Kanowitz J, Kemeny NE, et al: Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 14: 2959-2967, 1996
15. Petrelli N, Douglass HO Jr, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial-Gastrointestinal Tumor Study Group. J Clin Oncol 7:1419-1426, 1989
16. Camptosar [package insert]. Kalamazoo, Ml, Pharmacia & Upjohn Company, 2002
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
18. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-34, 2003
19. Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23 (in press)
20. Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
21. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004